ETON PHARMACEUTICALS INC (ETON) Stock News
NASDAQ:ETON - Nasdaq - US29772L1089 - Common Stock - Currency: USD
ETON Latest News, Press Relases and Analysis
Evaluating ETON PHARMACEUTICALS INC (NASDAQ:ETON) using Mark Minervini’s winning stock formula
A fundamental and technical analysis of (NASDAQ:ETON): Is ETON PHARMACEUTICALS INC (NASDAQ:ETON) suited for high growth investing?
Eton Pharmaceuticals to Report First Quarter 2025 Financial Results on Tuesday, May 13, 2025
Eton Pharmaceuticals to Report First Quarter 2025 Financial Results on Tuesday, May 13, 2025
DEER PARK, Ill., May 01, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical...
Eton Pharmaceuticals, Inc. (ETON) Earnings Expected to Grow: What to Know Ahead of Q1 Release
Eton Pharmaceuticals (ETON) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Mentions: TRDA
Eton Pharmaceuticals Announces Submission of NDA for ET-600 (Desmopressin Oral Solution)
Eton Pharmaceuticals Announces Submission of NDA for ET-600 (Desmopressin Oral Solution)
- NDA submitted for the treatment of central diabetes insipidus -- Expected 10-month review; commercial preparations underway for a potential Q1 2026...
Eton Pharmaceuticals Out-Licenses International Rights to Increlex®
Esteve Pharmaceuticals, S.A. will commercialize Increlex in all markets outside the U.S.
Eton Pharmaceuticals Out-Licenses International Rights to Increlex®
Esteve Pharmaceuticals, S.A. will commercialize Increlex in all markets outside the U.S....
Eton Pharmaceuticals Reports Fourth Quarter 2024 Financial Results
Eton Pharmaceuticals Reports Fourth Quarter 2024 Financial Results
Management to Hold Investor Day Conference Call Today at 10:00am ET Reported record product revenue of $11.6 million in Q4 2024, an increase of 59% over...
Eton Pharmaceuticals Announces Positive Pivotal Clinical Study Results for Product Candidate ET-600
Eton Pharmaceuticals Announces Positive Pivotal Clinical Study Results for Product Candidate ET-600
- Company’s patented desmopressin oral solution successfully passed pivotal bioequivalence study -- Company expects to submit New Drug Application (NDA) in...
Eton Pharmaceuticals to Host Virtual Investor Day and Release Fourth Quarter Earnings Results on March 18, 2025
Eton Pharmaceuticals to Host Virtual Investor Day and Release Fourth Quarter Earnings Results on March 18, 2025
DEER PARK, Ill., March 04, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (“Eton” or the
Eton Pharmaceuticals Announces Commercial Launch of Galzin® (zinc acetate) Capsules
Eton Pharmaceuticals Announces Commercial Launch of Galzin® (zinc acetate) Capsules
– Eton expects to significantly expand patient access to this critical treatment for Wilson disease patients –– $0 co-pay for all eligible patients and...
Eton Pharmaceuticals Expands Patent Portfolio with Issuance of New U.S. Patent for ET-600
Eton Pharmaceuticals Expands Patent Portfolio with Issuance of New U.S. Patent for ET-600
- Product has patent protection through 2044 - - Expected to be listed in the U.S. Food and Drug Administration’s (FDA) Orange Book upon the product’s...
Eton Pharmaceuticals Announces Extension of PDUFA Goal Date for ET-400
Eton Pharmaceuticals Announces Extension of PDUFA Goal Date for ET-400
DEER PARK, Ill., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical...
Eton Pharmaceuticals Advances Its Commitment to Rare Disease with the Acquisition of Galzin®
Eton Pharmaceuticals Advances Its Commitment to Rare Disease with the Acquisition of Galzin®
Adds an additional commercial and strategic rare disease product to Eton’s portfolioGalzin is FDA-approved for the treatment of the ultra-rare metabolic...
Eton Pharmaceuticals Closes Acquisition of Increlex® (mecasermin injection)
Eton Pharmaceuticals Closes Acquisition of Increlex® (mecasermin injection)
Acquisition bolsters Eton’s commercial pediatric endocrinology portfolioProduct is now available through AnovoRx, a specialty pharmacy dedicated to serving...
Eton Pharmaceuticals Announces Final Readout of PKU GOLIKE® Clinical Trial
Clinical Trial Demonstrates Clinical and Statistical Improvement in Metabolic Control During Prolonged Fasting in PKU Patients - Results Expected to Promote Awareness and Adoption of PKU GOLIKE®
Eton Pharmaceuticals Appoints Ipek Erdogan-Trinkaus as Chief Commercial Officer
Ms. Erdogan-Trinkaus brings a wealth of commercial leadership and expertise in sales and marketing from her tenure at leading global pharmaceutical...
Eton Pharmaceuticals Announces Acquisition of U.S. Rights to Amglidia (Glyburide Oral Suspension)
Eton Pharmaceuticals Announces Acquisition of U.S. Rights to Amglidia (Glyburide Oral Suspension)
Amglidia® has been approved by the European Medicines Agency (EMA) and is commercially available in EuropeStrong strategic fit with Eton’s existing...
Eton Pharmaceuticals Reports Third Quarter 2024 Financial Results
Eton Pharmaceuticals Reports Third Quarter 2024 Financial Results
Reported total revenue of $10.3 million and GAAP Net Income of $0.6 million, or $0.02 per diluted shareEntered into an asset purchase agreement to acquire...